Floatz logo

Naratriptan

Impulse Regulation Disorder

UMC UtrechtSmall moleculePhase 4 / ApprovedDormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Impulse Regulation Disorder cohort.

Asset / SponsorPhaseRating
carbidopa
Sandoz
Phase 4BB
LEVODOPA
University Hospital Bispebjerg and Frederiksberg
Phase 4BB
Naltrexone
University of Pennsylvania
Phase 4BB
Clonidine
Hospices Civils de Lyon
Phase 2B
Nalmefene
University Hospital, Clermont-Ferrand
Phase 2CCC

View all 9 →

Same molecule, other indications

Naratriptan is also rated in:

Post Traumatic HeadacheDormant
B
Indicative ·
56 / 100
View asset →
psychotic disorderDormant
B
Indicative ·
56 / 100
View asset →
antisocial personality disorderDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →